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he State of Periprocedural Antiplatelet Therapy
fter Recent Trials
ihar R. Desai, MD, MPH,* Deepak L. Bhatt, MD, MPH*†
oston, Massachusetts
he ability to mechanically dilate and treat stenoses in the coronary arteries opened a new chapter in
ardiovascular medicine. Percutaneous coronary intervention (PCI) has been shown to improve out-
omes among patients with acute coronary syndromes as well as improve symptoms among patients
ith stable coronary artery disease. Adjunctive antiplatelet therapy plays a critical role both in the
eriprocedural setting as well as in the long-term management of atherothrombosis. Over the past
everal years, clinical trials of novel compounds and treatment strategies have further reﬁned our phar-
acotherapeutic approach. Aspirin remains the cornerstone for antiplatelet therapy across the spec-
rum of ischemic heart disease. In contrast, studies of glycoprotein IIb/IIIa inhibitors suggest a more
imited role, particularly when used in addition to contemporary dual antiplatelet therapy. Clopidogrel,
he most widely used P2Y12 adenosine diphosphate receptor blocker—although having demonstrated
fﬁcacy in patients with ST-segment elevation myocardial infarction, non–ST-segment elevation acute
oronary syndrome, and stable coronary artery disease undergoing PCI—has several limitations, includ-
ng delay in onset, variability in response, and modest potency. The third-generation thienopyridine, prasug-
el, as well as nonthienopyridine inhibitors of the P2Y12 receptor such as ticagrelor and cangrelor address
hese shortcomings, offering more potent, consistent, and rapid platelet inhibition. Prasugrel and ticagrelor
ed to signiﬁcant reductions in adverse cardiovascular events, including cardiovascular mortality for the lat-
er, whereas cangrelor met noninferiority compared with 600 mg of clopidogrel in patients with ACS under-
oing PCI. There are myriad novel compounds at varying stages of development, including thrombin recep-
or antagonists whose role in the periprocedural and long-term setting will be deﬁned through further
tudy. Signiﬁcant questions regarding antiplatelet therapy remain unanswered, including the role of genetic
nd platelet function testing to “tailor therapy”; the optimal duration of therapy; and the optimal mecha-
ism to deliver high-quality, cost-effective antiplatelet therapy to all patients. (J Am Coll Cardiol Intv 2010;
:571–83) © 2010 by the American College of Cardiology Foundationw
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ercutaneous coronary intervention (PCI) has
een shown to improve outcomes among patients
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0, 2010, accepted April 15, 2010.ith acute coronary syndromes (ACS) as well
s significantly improve symptoms among patients
ith stable coronary artery disease (CAD) (1–4).
mportant advances in procedural techniques,
quipment, and devices have occurred in parallel
ith improvements in adjunctive antithrombotic
herapy. Given the importance of platelets in
therothrombosis, considerable interest has emerged
n optimizing pharmacotherapy both in the peripro-
edural setting as well as longer term (Fig. 1). In the
ake of several recent clinical trials investigating
ovel antiplatelet agents, we review the current state
f periprocedural antiplatelet therapy.
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572spirin
spirin has been the mainstay of periprocedural antiplatelet
herapy, regardless of PCI indication (i.e., stable angina vs.
CS). The ATC (Antiplatelet Trialists’ Collaboration)
tudy demonstrated an approximately 25% relative risk
eduction (RRR) in the cumulative incidence of vascular
eath, myocardial infarction (MI), or stroke with aspirin
ersus placebo (5). However, questions remain as to the
ptimal dose of aspirin. The ATC meta-analysis comparing
wide range of doses of aspirin found no incremental
eduction in ischemic events from 75 mg to 1,500 mg,
hereas gastrointestinal events were significantly increased
n subjects receiving more than 300 mg/day of aspirin.
Low-dose (75 to 100 mg/day)
aspirin was compared with high-
dose (300 to 325 mg/day) aspi-
rin in the CURRENT-OASIS
7 (Clopidogrel Optimal Loading
Dose Usage to Reduce Recur-
rent Events/Optimal Antiplate-
let Strategy for Interventions)
trial, a randomized trial of
25,087 patients with ACS,
among whom 17,232 underwent
PCI (6). There was no statisti-
cally significant difference in the
cumulative rate of the primary
end point, a composite of car-
diovascular (CV) death, MI, or
stroke between the 2 arms.
Moreover, there was no differ-
ence in the incidence of stent
thrombosis at 30 days. Of note,
there was no difference in major
bleeding, with the Thrombolysis
In Myocardial Infarction (TIMI)
or CURRENT definitions, al-
though there seemed to be a
higher rate of gastrointestinal
leeding in patients receiving high-dose aspirin therapy (0.24%
s. 0.38%, p  0.05).
lycoprotein IIb/IIIa Inhibitors
hree parenteral inhibitors of the glycoprotein IIb/IIIa
eceptor have been extensively studied in patients undergo-
ng PCI—abciximab, eptifibatide, and tirofiban. Earlier
nvestigations with these potent inhibitors of platelet aggre-
ation demonstrated reductions in adverse CV events across
everal settings, including PCI for stable CAD as well as
CS (7); however, recent data suggest a more limited role
bbreviations
nd Acronyms
CS  acute coronary
yndrome
DP  adenosine
iphosphate
AD  coronary artery
isease
V  cardiovascular
I  myocardial infarction
STE-ACS  non–ST-
egment elevation acute
oronary syndrome
CI  percutaneous
oronary intervention
RR  relative risk
eduction
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarction
ASP  vasodilator-
timulated phosphoproteinor these agents in the periprocedural setting. gEarly meta-analyses evaluating the efficacy of glyco-
rotein IIb/IIIa inhibition in patients with ACS or under-
oing PCI demonstrated significant reductions in major
dverse CV events, including a significant reduction in
ortality at 30 days and 6 months (8,9). However, many of
he early studies of glycoprotein IIb/IIIa inhibitors do not
eflect current clinical practice, because few patients received
oncomitant antiplatelet therapy with a thienopyridine. The
ore contemporary ISAR-REACT (Intracoronary Stent-
ng and Antithrombotic Regimen: Rapid Early Action for
oronary Treatment) trial showed no benefit of adjunctive
lycoprotein IIb/IIIa inhibition in subjects undergoing elective
CI who were pre-treated with 600 mg of clopidogrel (10).
imilar findings were noted in the ISAR-SWEET (Intracoro-
ary Stenting and Antithrombotic Regimen: is abciximab a
uperior Way to Eliminate Elevated Thrombotic risk in
iabetics) trial, which studied the same question in diabetic
atients (11).
Several early investigations of glycoprotein IIb/IIIa inhi-
ition among patients with non–ST-segment elevation
cute coronary syndrome (NSTE-ACS) demonstrated sig-
ificant RRRs in the rate of CV death or MI at 30 days,
anging from 31% to 83% (12–14). Once again, more
ontemporary studies of glycoprotein IIb/IIIa inhibitors have
ielded conflicting results, particularly in the setting of aggres-
ive pre-treatment with high-dose clopidogrel. The impact of
bciximab versus placebo was evaluated in the ISAR-REACT
trial of 2,022 patients with moderate- to high-risk ACS
ndergoing PCI, all of whom received 600 mg of clopidogrel
nd high-dose aspirin (15). Although the overall trial results
emonstrated a significant 3% absolute and 25% RRR with
djunctive abciximab, the benefit was limited to those with an
levation in biomarkers at presentation.
With the benefit of periprocedural glycoprotein IIb/IIIa
nhibition in NSTE-ACS seemingly limited to high-risk
atients, a significant outstanding clinical question was the
ptimal timing of treatment (i.e., routine early use or
elayed, provisional use). The EARLY-ACS (Early Glyco-
rotein IIb/IIIa Inhibition in Non-ST-Segment Elevation
cute Coronary Syndrome) trial was an international ran-
omized controlled trial of 9,492 patients with high-risk
STE-ACS planned for an invasive management strategy.
outine early use of eptifibatide was associated with a
onsignificant 8% RRR in the primary end point of death,
I, recurrent ischemia leading to urgent revascularization,
r need for thrombotic bailout at 96 h at the expense of
ignificantly increased rates of major bleeding (16). These
ndings were consistent with the findings from the
CUITY (Acute Catheterization and Urgent Intervention
riage) timing study (17).
Adjunctive antiplatelet therapy with glycoprotein IIb/IIIa
nhibitors has also been studied in patients with ST-
egment elevation myocardial infarction (STEMI) under-
oing fibrinolysis or reperfusion with primary PCI. Abcix-
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573mab remains the most well-studied agent in the primary
CI setting, and a meta-analysis of 11 randomized trials
emonstrated that use of adjunctive abciximab was associ-
ted with a significant reduction in mortality at 30 days and
p to 1 year without an associated increase in bleeding
Figure 1. Antiplatelet Pharmacotherapy
Receptors involved in platelet activation and aggregation as well as sites of ac
from Meadows et al. (74). (B) Adapted with permission from Angiolillo et al. (6
receptor; TxA2  thromboxane A2; VWF  von Willebrand factor.vents (18). These data notwithstanding, the efficacy of pbciximab in patients with STEMI undergoing primary
CI who were pre-treated with 600 mg of clopidogrel was
ecently questioned by the null findings of the BRAVE-3
Bavarian Reperfusion AlternatiVes Evaluation-3) trial,
hich evaluated left ventricular infarct size with single-
f both established and novel antiplatelet drugs. (A) Adapted with permission
P  adenosine diphosphate; GP  glycoprotein; PAR  protease-activatedtion o
6). ADhoton emission computed tomography imaging (19).
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574A facilitated PCI strategy employing a combination of
educed-dose fibrinolytic with intravenous abciximab was
ssociated with significantly reduced infarct size and higher
ate of complete ST-segment resolution (20), but the
INESSE (Facilitated Intervention with Enhanced Reper-
usion Speed to Stop Events) trial found no benefit in major
linical outcomes with a significant increase in bleeding
omplications (21).
Although it seems that the indications for use of glyco-
rotein IIb/IIIa antagonists continue to narrow, periproce-
ural antiplatelet therapy incorporating routine use of these
otent inhibitors of platelet aggregation has been wholly
uestioned with the use of bivalirudin as anticoagulant
upport for PCI. In the REPLACE-2 (Randomized
valuation in PCI Linking Angiomax to Reduced Clin-
cal Events-2) trial, bivalirudin with provisional glyco-
rotein IIb/IIIa inhibition was shown to be noninferior to
eparin plus planned glycoprotein IIb/IIIa inhibition in
,002 patients undergoing PCI, most of whom had been
re-treated with clopidogrel (22). The ACUITY trial, of
3,819 patients with moderate- to high-risk ACS who
lanned to undergo PCI, not only demonstrated the non-
nferiority of bivalirudin with provisional glycoprotein IIb/
IIa inhibition compared with heparin (unfractionated or
ow-molecular weight) with glycoprotein IIb/IIIa inhibi-
ion, but also met superiority for the net clinical end point,
hich included major bleeding events (23). Importantly,
hese findings were only applicable to the cohort of patients
ho received clopidogrel (24).
Finally, the HORIZONS-AMI (Harmonizing Out-
omes with RevasculariZatiON and Stents in Acute Myo-
ardial Infarction) trial compared bivalirudin plus provi-
ional glycoprotein IIb/IIIa with unfractionated heparin
lus planned glycoprotein IIb/IIIa in 3,602 patients with
TEMI undergoing primary PCI (25). Although there was
o difference in major adverse CV events at 30 days, there
as significantly less major bleeding with bivalirudin, driv-
ng the net clinical end point in favor of the direct
hrombin inhibitor. Moreover, use of bivalirudin was
ssociated with a 1.1% absolute risk reduction in the rate
f CV death at 30 days, which remained significant at 1
ear (26). One concern raised by the HORIZONS trial
as the significantly higher risk of acute stent thrombosis
n the bivalirudin arm in spite of potent background
ntiplatelet therapy (27).
hienopyridines
iclopidine, clopidogrel, and prasugrel are all oral, irrevers-
ble thienopyridine inhibitors of the platelet P2Y12 adeno-
ine diphosphate (ADP) receptor. Dual antiplatelet therapy
ith aspirin and ticlopidine led to a 75% RRR in the rate of
V death, MI, need for bypass surgery, or repeat angio-
lasty and an 86% RRR in stent thrombosis when compared cith aspirin and phenprocoumon, an anticoagulant (28).
urther investigation of the impact of pre-treatment, which
emonstrated reductions in adverse CV events, refined the
ptimal periprocedural use of ticlopidine (29,30). Accumu-
ated data showed that clopidogrel was preferable to ticlo-
idine due to better tolerability and at least equivalent
fficacy (31).
The primary results and subsequent analyses of the
REDO (Clopidogrel for the Reduction of Events During
bservation) trial demonstrated the benefit of clopidogrel
re-treatment as well as long-term dual antiplatelet therapy
n stable patients undergoing elective PCI (32,33) whereas
he efficacy of clopidogrel in patients with NSTE-ACS was
stablished in the CURE (Clopidogrel in Unstable Angina
o Prevent Recurrent Ischemic Events) trial (34). Approx-
mately 20% of the overall CURE cohort underwent PCI,
mong whom clopidogrel pre-treatment was associated
ith a significant 30% RRR in the cumulative incidence
f CV death, MI, or urgent target vessel revascularization
t 28 days and a 31% RRR in the rate of CV death or MI
t 1 year (35).
In STEMI, intensification of antiplatelet therapy with
spirin and clopidogrel was shown to be beneficial in both
he COMMIT-CCS (Clopidogrel and Metoprolol in Myo-
ardial Infarction Trial/Second Chinese Cardiac Study) 2
36) and CLARITY–TIMI (Clopidogrel as Adjunctive
eperfusion Therapy–Thrombolysis In Myocardial Infarc-
ion) 28 (37) trials. The PCI-CLARITY study, a pre-
pecified analysis of 1,863 patients, evaluated the impact of
lopidogrel pre-treatment versus treatment at the time of
ntervention (38). The former was associated with a highly
ignificant 41% RRR in the primary end point, a composite
f CV death, MI, or stroke at 30 days without an increase
n major bleeding complications.
Although the efficacy of early- and long-term therapy
ith clopidogrel had been established for patients undergo-
ng PCI across the spectrum of ischemic heart disease, there
emained several important limitations in its use for peripro-
edural platelet inhibition. For instance, clopidogrel is a
ro-drug, and even with a 300-mg loading dose, there is an
pproximately 6-h delay before substantial ADP receptor
ntagonism. The CURRENT-OASIS 7 (6) trial investi-
ated the role of a more intensive clopidogrel regimen,
pecifically a 600-mg load followed by 150 mg daily for 6
ays, followed by 75 mg daily versus conventional dosing
ith a 300-mg load followed by 75 mg daily in 25,087
atients across the spectrum of ACS. Among the 17,232
atients with ACS who underwent PCI, the “double-dose”
lopidogrel strategy resulted in a 15% RRR in the composite
nd point of CV death, MI, or stroke and a 42% RRR in
tent thrombosis with a slight increase in major or severe
leeding events.
Substantial interindividual variability in the response tolopidogrel in general and hyporesponsiveness or resistance
i
d
e
w
t
P
C
s
d
a
a
t
i
H
o
t
i
v
u
c
g
d
A
t
w
s
a
w
b
i
V
(
l
A
A
m
u
T
d
A
(
a
c
2
m
o
t
c
r
r
c
u
i
i
t
p
a
n
C
a
i
e
a
t
e
c
C
i
w
i
t
d
i
o
i
d
o
p
i
T
w
t
A
P
f
3
A
a
o
a
T
g
R
w
b
p
a
t
s
p
a
g
s
p
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 6 , 2 0 1 0 Desai and Bhatt
J U N E 2 0 1 0 : 5 7 1 – 8 3 Periprocedural Antiplatelet Therapy
575n particular is another limitation (39). Several studies had
emonstrated that a diminished response to clopidogrel,
stimated to occur in one-third of patients, is associated
ith an increased risk of adverse CV events, including stent
hrombosis (40). The recently completed POPULAR (Do
latelet Function Assays Predict Clinical Outcomes in
lopidogrel-Pretreated Patients Undergoing Elective PCI)
tudy formally evaluated 8 distinct platelet function tests and
emonstrated the ability of light transmittance aggregometry
s well as the VerifyNow P2Y12 and Plateletworks bedside
ssays to detect high residual platelet reactivity, which then
ranslated into increased rates of major adverse events, includ-
ng death, MI, stent thrombosis, and stroke at 1 year (41).
owever, the incremental ability of these tests to predict risk
ver and above clinical factors was modest. Bonello et al. (42)
ested the impact of a tailored approach to antiplatelet therapy
n 162 clopidogrel-resistant patients, as determined by the
asodilator-stimulated phosphoprotein (VASP) assay, sched-
led to undergo PCI. Subjects were randomized to usual
are—thereby proceeding to intervention—or to a “VASP-
uided” strategy in which they received iterative loading
oses of 600 mg of clopidogrel until the VASP was 50%.
t 30 days, there were 2 CV deaths, 4 cases of stent
hrombosis, and 2 cases of repeat revascularization, all of
hich occurred in the control arm. Although this was a
mall study, the concept of using platelet function testing
nd subsequently tailoring antiplatelet therapy in patients
ith clopidogrel resistance who are undergoing PCI is
eing evaluated in several large randomized trials, includ-
ng the GRAVITAS (Gauging Responsiveness With A
erifyNow Assay—Impact On Thrombosis And Safety)
NCT00645918), DANTE (Dual Antiplatelet Therapy Tai-
ored on the Extent of Platelet Inhibition) (NCT00774475),
RCTIC (Double Randomization of a Monitoring Adjusted
ntiplatelet Treatment Versus a Common Antiplatelet Treat-
ent for DES Implantation, and Interruption Versus Contin-
ation of Double Antiplatelet Therapy) (NCT00827411), and
RIGGER-PCI (Testing Platelet Reactivity In Patients Un-
ergoing Elective Stent Placement on Clopidogrel to Guide
lternative Therapy With Prasugrel) (NCT00910299) trials
Table 1). Importantly, however, the most prevalent cause of
ntiplatelet “resistance” outside the hospital seems to be non-
ompliance (43).
Clopidogrel is a pro-drug that is activated through a
-step, cytochrome P450—mediated oxidation. As such, its
etabolism and hence the generation of the active metab-
lite are influenced by genetic polymorphisms and suscep-
ible to drug–drug interactions, which could have important
linical consequences. In fact, carriers of the CYP2C19*2
educed function allele have been shown to have significant
eductions in the amount of the active metabolite of
lopidogrel as well as less platelet inhibition. These individ-
als are at significantly increased risk for adverse CV events,
ncluding a 3-fold increase in stent thrombosis (44). Thus, tn addition to platelet function testing, genetic testing for
he presence of the *2 allele might prove to be useful in the
eriprocedural setting to possibly individualize and optimize
ntiplatelet therapy (45). Future prospective studies are
ecessary before broadly endorsing such an approach.
Proton pump inhibitors are competitive inhibitors of the
YP2C19 enzyme and thus are mechanistically capable of
ltering the pharmacokinetic, pharmacodynamic, and clin-
cal effect of clopidogrel. In fact, there was ample ex vivo
vidence highlighting such an interaction, which led to
dvisories from both the U.S. Food and Drug Adminis-
ration and European Medicines Agency (46,47). How-
ver, the only randomized trial evaluating the impact of
lopidogrel and omeprazole versus clopidogrel alone, the
OGENT (Clopidogrel and the Optimization of Gastro-
ntestinal Events) trial (48), in approximately 3,600 patients
ith ACS or after PCI revealed no significant adverse
nteraction and, in fact, demonstrated a significant reduc-
ion in gastrointestinal bleeding events. These preliminary
ata provide reassurance regarding the use of proton pump
nhibitors with clopidogrel in patients who need both forms
f therapy, although evaluation of the final published results
s necessary (49).
The third-generation thienopyridine, prasugrel, ad-
ressed many of the limitations of clopidogrel, because it
ffered more potent, consistent, and rapid inhibition of the
latelet P2Y12 receptor. The 2 compounds were compared
n the TRITON–TIMI 38 (TRial to assess Improvement in
herapeutic Outcomes by optimizing platelet inhibitioN
ith prasugrel–Thrombolysis In Myocardial Infarction)
rial (50) of 13,608 patients with moderate- to high-risk
CS, including STEMI, all planned to undergo PCI.
rasugrel was administered with a 60-mg loading dose
ollowed by 10 mg daily, and clopidogrel was given as a
00-mg loading dose and 75 mg daily as maintenance dose.
t 15 months, treatment with prasugrel was associated with
2.3% absolute and 19% relative risk reduction in the rate
f CV death, MI, or stroke at the expense of a small
bsolute but statistically significant increase in the rate of
IMI major bleeding not related to coronary artery bypass
raft surgery as well as fatal bleeding. The rate of Academic
esearch Consortium definite or probable stent thrombosis
as reduced by 52% with more potent ADP receptor
lockade, irrespective of stent type. Among the 12,844
atients who underwent PCI and stenting, prasugrel was
ssociated with a significant reduction in adverse CV events
hat was consistent across stent type (51). In pre-specified
ubgroup analyses, treatment with prasugrel seemed to be
articularly effective in subjects with diabetes mellitus (52)
nd those presenting with STEMI (53). In both of these
roups, prasugrel as compared with clopidogrel led to
ignificant reductions in ischemic events without an accom-
anying increase in the rate of major bleeding complica-
ions. Conversely, in the trial as a whole, among subjects 75
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576Table 1. Ongoing Trials of Antiplatelet Therapy
Clinical Trial
(Registry No.) Study Population Study Arms Primary End Point
ACCOAST
(NCT01015287)
4,100 patients with NSTEMI planned
to undergo PCI
Randomized to pre-treatment with prasugrel (30 mg
at time of diagnosis with additional 30 mg at
PCI) vs. prasugrel (60 mg) at PCI. Maintenance
therapy in both arms will be 10 mg daily with
dose reduction to 5 mg in patients 75 yrs and
body weight 60 kg
CV death, MI, stroke, urgent
revascularization, or GP
IIb/IIIa inhibitor bailout at
7 days
ARCTIC
(NCT00827411)
2,500 patients undergoing elective
PCI with DES
Initial randomization to tailored antiplatelet therapy
with VerifyNow P2Y12 vs. standard dual
antiplatelet therapy. Subsequent randomization
after 12 months of patients who remain event-
free to discontinuation of antiplatelet therapy or
continuation of therapy
Death, MI, stroke, urgent
coronary revascularization,
or stent thrombosis
assessed at 1 yr; death,
MI, stroke, urgent
coronary revascularization,
or stent thrombosis at
6–18 months after second
randomization
DANTE Trial
(NCT00774475)
442 patients with NSTE-ACS
undergoing PCI with stent
implantation found to have high
residual platelet reactivity with
the VerifyNow P2Y12
Randomized to 75 mg of clopidogrel or 150 mg of
clopidogrel
CV death, MI, or target vessel
revascularization at
6 months and 1 yr
DAPT
(NCT00977938)
20,645 subjects undergoing PCI Subjects in the overall cohort who are free from
death, MI, stroke, repeat revascularization, stent
thrombosis, or major bleeding at 12 months will
be randomized to 18 additional months of dual
antiplatelet therapy or aspirin and placebo
CV death, MI, and stroke at
33 months; stent
thrombosis at 33 months
GRAVITAS
(NCT00645918)
2,783 subjects after DES placement
for stable CAD or NSTE-ACS will
have platelet function testing
done with VerifyNow P2Y12
Patients with high residual platelet reactivity will be
randomized to receive standard-dose clopidogrel
(75 mg daily) or high-dose clopidogrel (600 mg
load, 150 mg daily). A random sample of patients
without high residual platelet reactivity will also
be enrolled and will receive 75 mg of clopidogrel
daily
CV death, MI, and deﬁnite/
probable stent thrombosis
at 6 months
INNOVATE-PCI
(NCT00751231)
Phase II trial in 800 patients
undergoing elective PCI
Randomized to clopidogrel (300/600 mg load,
followed by 75 mg daily) or elinogrel (80 mg IV
bolus administered before PCI, followed by twice
daily dosing of oral 50 mg, 100 mg, or 150 mg)
No pre-speciﬁed primary
end point
LANCELOT 201
(NCT00312052)
Phase II trial of 600 patients
with CAD
Randomized to E5555 (50 mg, 100 mg, or 200 mg
daily) or placebo
Safety and tolerability
(6 months)
LANCELOT 202
(NCT00548587)
Phase II trial of 600 patients
with ACS
Randomized to E5555 (50 mg, 100 mg, or 200 mg
daily) or placebo
Safety and tolerability
(12 weeks)
TRA-CER
(NCT00527943)
12,500 subjects with ACS Randomized to SCH 530348 (40 mg loading dose,
2.5 mg daily) vs. placebo
CV death, MI, stroke,
recurrent ischemia with
repeat hospital stay, and
urgent coronary
revascularization at end
of study
TRA-2P-TIMI 50
(NCT00526474)
26,450 patients with history of CAD,
CVA, or PAD
Randomized to SCH 530348 (2.5 mg daily) vs.
placebo
CV death, MI, stroke, and
urgent coronary
revascularization at end
of study
TOPAS-1
(NCT00914368)
Phase II trial of 450 patients who
have either had or not had stent
thrombosis or MI within
6 months of PCI while on dual
antiplatelet therapy
All subjects will undergo platelet function testing
with both VerifyNow P2Y12 and VASP assays
Establish VerifyNow P2Y12
(PRU) and VASP (PRI, %)
cutoff level of platelet
inhibition in patients with
and without clinical
events.
TRIGGER-PCI
(NCT00910299)
2,150 subjects with high residual
platelet reactivity with the
VerifyNow P2Y12 after elective
PCI with DES
Randomized to prasugrel (60 mg load, 10 mg daily)
vs. clopidogrel (75 mg daily)
CV death or MI at 6 monthsContinued on next page
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577ears of age or older, those weighing60 kg, and those with
prior history of transient ischemic attack (TIA) or stroke,
he balance of safety and efficacy favored clopidogrel over
rasugrel (50). Furthermore, prasugrel does not seem to be
rone to alterations in its pharmacokinetics, pharmacody-
amics, or clinical efficacy on the basis of genetic polymor-
hisms (54). There are several ongoing clinical trials involv-
ng prasugrel (Table 1), including the TRILOGY-ACS
Comparison of Prasugrel and Clopidogrel in Acute
oronary Syndrome Subjects Trial) (NCT00699998),
CCOAST Comparison of Prasugrel at PCI or Time of
iagnosis of Non-ST Elevation Myocardial Infarction
rial) (NCT01015287), and TRIGGER PCI trials
NCT00910299).
ilostazol
ilostazol, a reversible inhibitor of phosphodiesterase III
hat has been approved for use in patients with peripheral
rterial disease, has also been tested in patients undergoing
CI. Several small studies with short follow-up intervals
ave demonstrated that therapy with aspirin and cilostazol
s as effective as treatment with aspirin and ticlopidine in
atients undergoing elective stenting (55). Compared with
onventional dual antiplatelet therapy with aspirin and a
hienopyridine, the addition of cilostazol (so-called “triple
ntiplatelet therapy”) has produced conflicting results (56–58).
onthienopyridine P2Y12 Inhibitors
ntensification of antiplatelet therapy with thienopyridine
nhibitors of the P2Y12 receptor represented a major step
orward in PCI. One of the limitations of this entire class of
gents is that they are irreversible ADP receptor antago-
ists, particularly problematic for patients with 3-vessel or
eft-main CAD who require surgical revascularization that
ust then be delayed several days to allow recovery of
Table 1. Continued
Clinical Trial
(Registry No.) Study Population
TRILOGY-ACS
(NCT00699998)
10,300 patients with NSTE-ACS
being initially medically
managed
Ran
ACCOAST Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST ElevationMyocardial Inf
Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Inter
cardiovascular; CVA cerebrovascular accident; DANTE Dual Antiplatelet Therapy Tailored on th
glycoprotein IIb/IIa receptor; GRAVITAS Gauging Responsiveness With A VerifyNow Assay—Impa
Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI; LANCELOT 201 Safety and Tolerability o
LANCELOT202 Safety andTolerability of E5555and Its Effects onMarkers of Intravascular Inflamma
elevation acute coronary syndrome; NSTEMI non–ST-segment elevation myocardial infarction; P
PRU  platelet reactivity unit; TIMI  Thrombolysis In Myocardial Infarction; TOPAS-1  Tailoring
PreventingHeartAttack andStroke inPatientsWithAcuteCoronary Syndrome; TRA-2P-TIMI 50Tri
TRIGGER-PCI  Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on C
Clopidogrel in Acute Coronary Syndrome Subjects; VASP vasodilator-stimulated phosphoproteinlatelet function. Ticagrelor and cangrelor are 2 novel,eversible, ADP receptor antagonists—the former is an oral
gent, whereas the latter is parenterally administered. Both
ompounds provide more potent, rapid, and consistent
latelet inhibition compared with clopidogrel (59). In the
LATO (Study of Platelet Inhibition and Patient Out-
omes) trial, 18,624 patients across the spectrum of ACS
ere randomized to treatment with ticagrelor (180-mg load,
ollowed by 90 mg twice daily maintenance) or clopidogrel
300- to 600-mg load, followed by 75 mg daily mainte-
ance) (60). At 1 year, there was a highly significant, 16%
RR in the rate of CV death, MI, or stroke with ticagrelor
ompared with clopidogrel (Fig. 2). The benefit of ticagrelor
as seen by 30 days and persisted throughout the study period.
n the overall trial population, there was also a significant 1.1%
Study Arms Primary End Point
ed to prasugrel (30 mg load if
istered, followed by 5 mg or 10 mg
nance) or clopidogrel (300 mg load if
istered, followed by 75 mg daily)
CV death, MI, or stroke at
end of study
Trial; ACS acute coronary syndrome; ARCTICDouble Randomization of a Monitoring Adjusted
Versus Continuation of Double Antiplatelet Therapy Trial; CAD  coronary artery disease; CV 
t of Platelet Inhibition; DAPT Dual Antiplatelet Therapy; DES drug-eluting stents; GP IIb/IIIa
hrombosis And Safety; INNOVATE-PCI A Phase 2 Safety and Efficacy Study of PRT060128, a Novel
and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease;
SubjectsWithAcuteCoronary Syndrome;MImyocardial infarction;NSTE-ACSnon–ST-segment
eripheral artery disease; PCI percutaneous coronary intervention; PRI platelet reactivity index;
let Inhibition to Avoid Stent Thrombosis; TRA-CER  Trial to Assess the Effects of SCH 530348 in
ess theEffects of SCH530348 inPreventingHeartAttack andStroke inPatientsWithAtherosclerosis;
rel to Guide Alternative Therapy With Prasugrel; TRILOGY-ACS  Comparison of Prasugrel and
Figure 2. Primary Results of the PLATO Trial
Primary results of the PLATO (Study of Platelet Inhibition and Patient Out-
comes) trial (ticagrelor vs. clopidogrel in acute coronary syndromes). Cumu-
lative Kaplan-Meier estimates of the rate of the primary efﬁcacy end point
(death from vascular causes, myocardial infarction, or stroke) for ticagrelor
and clopidogrel at 12 months. Reprinted with permission from Wallentindomiz
admin
mainte
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arction
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ct On T
f E5555
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578bsolute risk reduction in death from vascular causes, a 1.4%
bsolute risk reduction in all-cause death, and a 33% RRR in
he rate of definite stent thrombosis with ticagrelor. Although
ajor bleeding, as defined in the study protocol was not
ignificantly increased between groups, use of ticagrelor was
ssociated with an increased rate of major bleeding not related
o coronary artery bypass graft surgery as well as a numerical
xcess of intracranial hemorrhage. Ventricular pauses of at least
s and dyspnea were seen more commonly in subjects
eceiving ticagrelor, as were increases in serum uric acid and
reatinine concentrations. The pre-specified analysis of pa-
ients who were managed with an early invasive strategy
irrored the findings in the overall study cohort with a
ignificant 16% RRR in adverse CV events as well as a
Figure 3. Primary Results of the PLATO-Invasive Trial
Primary results of the PLATO-Invasive trial (ticagrelor vs. clopidogrel in
patients with acute coronary syndromes managed with an invasive strat-
egy). Cumulative Kaplan-Meier estimates of the rate of the primary efﬁcacy
end point (death from vascular causes, myocardial infarction, or stroke) for
ticagrelor and clopidogrel at 12 months among patients managed with an
invasive strategy. Reprinted with permission from Cannon et al. (61).
Table 2. Pre-Specified and Exploratory Efficacy End Points for Cangrelor and
End Point
Cangrelor Gro
(n  3,889
Adjudicated end points
1° end point: death, MI, or ischemia-driven
revascularization
290 (7.5)
MI 278 (7.1)
Ischemia-driven revascularization 13 (0.3)
Death from any cause 8 (0.2)
Stent thrombosis 7 (0.2)
Stroke 6 (0.2)
Q-wave MI 4 (0.1)
Exploratory end points
Death, Q-wave MI, or ischemia-driven revascularization 23 (0.6)
Death, Q-wave MI, or stent thrombosis 18 (0.5)
Data presented as n (%) unless otherwise indicated. Reprinted with permission from Harrington et
CHAMPION Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet InSTEMI ST-segment elevation myocardial infarction.eduction in all-cause mortality (Fig. 3) (61). Among patients
ith STEMI, the cumulative rate of the primary end point was
lso significantly reduced with ticagrelor and, notably, without
n accompanying increase in the bleeding complications (62).
Cangrelor offers potent (90%) platelet inhibition within
inutes of infusion that is rapidly reversible, such that
latelet function normalizes within 60 min of discontinua-
ion of infusion. Its efficacy in patients undergoing PCI was
valuated in the CHAMPION (Cangrelor versus Standard
herapy to Achieve Optimal Management of Platelet
nhibition) PCI and CHAMPION PLATFORM trials.
he former randomly assigned 8,877 patients undergoing
CI, 85% with ACS, to receive cangrelor infusion (30-
g/kg bolus followed by 4-g/kg infusion) or 600 mg of
lopidogrel within 30 min of intervention (63). Patients
nitially receiving cangrelor received 600 mg of clopidogrel
fter an average infusion time of 2.1 h. The primary end
oint, a composite of death, MI, or ischemia-driven revas-
ularization at 48 h, occurred in 7.5% of subjects in the
angrelor arm and 7.1% in the clopidogrel arm (Table 2).
here was also no statistically significant difference in the
ate of stent thrombosis at 48 h or in the combined ischemic
nd point at 30 days. However, cangrelor was demonstrated
o be noninferior to 600 mg of clopidogrel.
The CHAMPION PLATFORM trial included 5,326
atients with NSTE-ACS who had undergone diagnostic
ngiography and were found to have CAD amenable to
ercutaneous revascularization (64). Patients were randomly
ssigned to receive either cangrelor (30-g/kg bolus fol-
owed by an infusion of 4 g/kg for 2 to 4 h) or placebo for
he duration of the PCI procedure. Subjects initially in the
lacebo group received a 600-mg loading dose of clopi-
ogrel at the conclusion of the intervention, whereas those
nitially in the active treatment arm received 600 mg of
ogrel at 48 h Among Patients Without STEMI in the CHAMPION PCI Trial
Clopidogrel Group
(n  3,865) Odds Ratio (95% CI) p Value
276 (7.1) 1.05 (0.88–1.24) 0.59
256 (6.6) 1.09 (0.91–1.29) 0.36
23 (0.6) 0.56 (0.28–1.11) 0.10
5 (0.1) 1.59 (0.52–4.87) 0.42
11 (0.3) 0.63 (0.25–1.63) 0.34
7 (0.2) 0.85 (0.29–2.54) 0.77
10 (0.3) 0.40 (0.12–1.27) 0.12
34 (0.9) 0.67 (0.39–1.14) 0.14
23 (0.6) 0.78 (0.42–1.44) 0.42
; CI confidence interval; MImyocardial infarction; PCI percutaneous coronary intervention;Clopid
up
)
al. (63).
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579lopidogrel after conclusion of the cangrelor infusion. At
8 h, there was a nonsignificant 13% RRR in the cumulative
ncidence of death, MI, or ischemia driven revascularization
Fig. 4). There was, however, a significant reduction in the
econdary end points of all-cause death and stent thrombo-
is associated with cangrelor compared with placebo at 48 h.
Neither of the CHAMPION trials had a primary safety
Figure 4. Primary Results of the CHAMPION-PLATFORM Trial
Primary results of the CHAMPION-PLATFORM (Cangrelor versus Standard Thera
dogrel in ACS). Cumulative Kaplan-Meier estimates of the rate of the primary e
tion) for cangrelor and clopidogrel at 48 h in the CHAMPION-PLATFORM trial.nd point. Instead, they reported the rates of various cleeding end points, including TIMI, ACUITY, and
lobal Use of Strategies to Open Occluded Arteries
GUSTO). There was no difference in GUSTO severe or
oderate or TIMI major bleeding in either study, although
here was a significantly increased rate of ACUITY major
leeding in the PLATFORM trial and a trend toward
igher ACUITY major bleeding in the PCI trial (p 0.06),
Achieve Optimal Management of Platelet Inhibition) trial (cangrelor vs. clopi-
y end point (death, myocardial infarction, or ischemia-driven revasculariza-
ted with permission from Bhatt et al. (64).py to
fﬁcaconsisting entirely of an excess of groin hematomas (63,64).
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580Elinogrel (PRT060128)—a reversible, potent P2Y12 in-
ibitor of the platelet ADP receptor available in both
ntravenous and oral preparations—was studied in a phase II
rial, the ERASE-MI (Early Rapid Reversal of Platelet
hrombosis with Intravenous Elinogrel before PCI to
ptimize Reperfusion in Acute Myocardial Infarction) trial
65), of 70 patients with STEMI undergoing primary PCI.
lthough there was no significant benefit comparing eli-
ogrel versus placebo, there were no safety concerns raised
y the 4 different doses that were tested. Elinogrel will be
he subject of additional clinical trials, including the
NNOVATE-PCI (A Phase 2 Safety and Efficacy Study of
RT060128, a Novel Intravenous and Oral P2Y12 Inhibi-
or, in Non-Urgent PCI) trial (NCT00751231).
hrombin Receptor Antagonists
lthough ADP is an important mediator of platelet activation,
nd ADP antagonism has been shown to be quite efficacious in
oth the periprocedural and long-term settings, thrombin is an
ven more potent agonist of platelet activation and therefore an
ttractive therapeutic target. Moreover, thrombin inhibition
ight allow selective blockade of platelets involved in athero-
hrombosis while preserving platelet function in primary he-
ostasis, thus representing a safer alternative for intensifying
ntiplatelet therapy (66). Orally active thrombin receptor
ntagonists SCH530348 and E5555 are currently being tested
n clinical trials (Table 1).
he Road Ahead for Periprocedural Antiplatelet Therapy
he capability to mechanically dilate and treat stenoses in
he coronary arteries represented a major change in the
anagement of ischemic heart disease. Since 1977, when
he first angioplasty procedure was successfully performed,
remendous advances have been made in the techniques,
evices, and therapies offered in the cardiac catheterization
aboratory. These improvements have been paralleled by
dvances in adjunctive pharmacotherapy. By exploring both
he historical context of antiplatelet therapy as well as
eviewing recent therapeutic developments, we have sought
o provide a contemporary overview of periprocedural anti-
latelet therapy.
With myriad choices for antiplatelet agents (not to
ention anticoagulants), selection of the optimal peripro-
edural regimen can be quite a daunting task. Background
herapy with aspirin continues to be the unwavering, cor-
erstone of antiplatelet therapy. Broadly speaking, the trend
oward more potent inhibition of the platelet P2Y12 recep-
or has catalyzed a steady decline in the need for routine
djunctive glycoprotein IIb/IIIa inhibition, which will only
e hastened by the increasing use of bivalirudin in routine
linical practice. At this point, their most compelling
ndication remains use in the catheterization laboratory to
upport complex coronary interventions in high-risk pa- uients or as a bailout therapy once angiographic complica-
ions occur. However, novel approaches being studied such
s intracoronary delivery of glycoprotein IIb/IIIa inhibitors
ight yet lead to resurgence in their use (67).
Clopidogrel will likely remain the most commonly used
djunctive agent in the periprocedural setting in the short
erm, the advent of several new platelet antagonists of the
2Y12 receptor notwithstanding. The results of the
RITON and PLATO trials offer empirical verification of
he intuitive hypothesis that more potent antiplatelet inhi-
ition would yield greater reduction in adverse ischemic
vents at the expense of more bleeding complications.
lthough the design of the TRITON–TIMI 38 trial had
ome limitations, including comparison with 300 mg of
lopidogrel and lack of pre-treatment, prasugrel deserves to
lay an important role in patients with ACS undergoing
CI when the coronary anatomy has been delineated. We
eel that it deserves particular consideration in patients with
TEMI and in those with diabetes, where the balance of
enefit and risk should be maximized. Moreover, we feel that
t should be the antiplatelet agent of choice in those who had
hrombotic occlusion of an intracoronary stent while actually
aking clopidogrel and, if future studies validate, also in those
atients with residual platelet reactivity despite treatment with
lopidogrel. The role of pre-treatment with prasugrel, the
mpact of a lower maintenance dose (i.e., 5 mg) in elderly
atients and the underweight and its role in patients with stable
AD undergoing PCI remain outstanding questions.
Although the PLATO trial results were impressive,
icagrelor was not tested uniformly against a 600-mg load-
ng dose of clopidogrel or against a 150-mg maintenance
ose of clopidogrel in the PLATO trial, requires twice daily
osing, and has yet to be approved by the Food and Drug
dministration. The requisite twice daily dosing, although
heoretically capable of antagonizing platelets entering the
irculation after the first dose, clearly poses a challenge for
atient compliance compared with a once-daily dosing
egimen. Furthermore, its reversibility, which in the imme-
iate periprocedural setting is certainly an asset, might
ecome a liability in its long-term use where nonadherence
ight expose patients to a more immediate risk of adverse
schemic events, including stent thrombosis. Finally, the risk
f excess bleeding for patients undergoing emergent coro-
ary artery bypass graft surgery would not be obviated with
his compound, which would still require a few days for
eturn of normal platelet function (68). Despite these
actors, the results of the PLATO trial are unambiguous
nd make it difficult to foresee how practitioners could
efrain from routinely using an agent in compliant patients
ith ACS undergoing PCI if it is approved.
The CHAMPION trials were instructive on many fronts,
ncluding highlighting the difficulty of ascertaining peripro-
edural MI in patients with baseline biomarker elevation
ndergoing PCI soon after presentation. In some respects,
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581oth the CHAMPION-PLATFORM and PCI trials are
ubject to the same limitation as TRITON–TIMI 38 in
hat they both required performance of a diagnostic
ngiogram with demonstration of occlusive coronary
isease amenable to PCI before randomization. As a result,
either CHAMPION study protocol tested cangrelor against
everal hours of pre-treatment with clopidogrel. Taken to-
ether, both also highlight the clinical efficacy of 600 mg of
lopidogrel, which proved to be a high hurdle for cangrelor to
vercome. In spite of the inability of cangrelor to demonstrate
uperiority in these trials, its noninferiority compared with 600
g of periprocedural clopidogrel could enable it to fill a
onspicuous gap in clinical practice, specifically, facilitating
otent periprocedural platelet inhibition in patients unable to
olerate or properly absorb oral medications, of particular
oncern in patients with cardiogenic shock or those who are
omiting or who are heavily sedated (69). These observations
s well as promising post hoc exploratory analyses of the
HAMPION trials might merit further study of cangrelor
70).
The preceding decade has witnessed an impressive ex-
ansion of the pharmacotherapeutic arsenal in CV medi-
ine. Despite seemingly countless compounds, innumerable
rials, and a limitless body of published data, several signif-
cant questions regarding antiplatelet therapy remain unan-
wered. For one, the optimal length of dual antiplatelet
herapy in patients undergoing PCI with drug-eluting stents
emains a point of controversy. The ongoing DAPT (Dual
ntiplatelet Therapy) trial (NCT00977938) will compare
tandard therapy for 12 months with extended therapy for
0 months in 15,000 patients receiving drug-eluting stents,
egardless of indication. Furthermore, platelet function
esting and genetic testing might produce a paradigm-shift
n antiplatelet therapy. The promise of “personalized medicine”
ould conceivably be realized with the application of these
ools, although admittedly still in their infancy and in need of
igorous evaluation. Given the recent discussions in the U.S.
bout health care reform, cost control, and system realignment,
eriprocedural antiplatelet therapy is ripe for meaningful com-
arative effectiveness and cost-effectiveness research. In fact,
ith generic clopidogrel coming soon, there is a real possibility
hat “tailored therapy” would allow us to leverage scientific
dvances into improved outcomes as well as cost savings. The
eed for carefully designed studies that acknowledge these
roader policy issues cannot be overstated. Finally, antiplatelet
herapy has proven not to be immune from the quality issues
hat plague many areas of our health care system. Despite
idespread dissemination of clinical practice guidelines and a
eries of national initiatives to improve guideline adherence,
he quality of care delivered to patients with ACS remains
uboptimal. Specifically, the underuse, overuse, and misuse of
ntiplatelet medications remains a serious problem deserving
ttention (71–73).eprint requests and correspondence: Dr. Deepak L. Bhatt,
righam and Women’s Hospital, 75 Francis Street, PBB-146, Bos-
on, Massachusetts 02115. E-mail: dlbhattmd@post.harvard.
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